Journal article
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
Mark J McKeage, Martin Reck, Michael B Jameson, Mark A Rosenthal, David Gibbs, Paul N Mainwaring, Lutz Freitag, Richard Sullivan, Joachim Von Pawel
LUNG CANCER | ELSEVIER IRELAND LTD | Published : 2009
Abstract
This single-arm phase II study evaluated the tumor-vascular disrupting agent ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) plus standard therapy of carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). This ASA404 dose is 50% higher than that used in previous phase II studies. Thirty patients with histologically confirmed stage IIIb or IV NSCLC previously untreated with chemotherapy received carboplatin AUC 6mg/mlmin plus paclitaxel 175mg/m(2) plus ASA404 1800mg/m(2) every 21 days for up to six cycles. The addition of ASA404 1800mg/m(2) to standard therapy produced little change in the systemic exposure of either total or free c..
View full abstractGrants
Funding Acknowledgements
This work was supported by Antisoma Research Limited, London, UK. We thank the patients, families, study staff and the Antisoma clinical development team.